The International Regulatory Affairs Network
09.03.2010
biospace med Signs Distribution Agreement with Odelft for Benelux
biospace med (www.biospacemed.com), an emerging medical technology company based in Paris, and Oldelft Benelux, a renowned specialist in medical diagnostic imaging, announced today the signature of an exclusive distribution agreement of EOS, the world's first ultra-low-dose 2D|3D imager. The agreement will cover the distribution of EOS for the Benelux area (Belgium, The Netherlands & Luxembourg).
biospace med (www.biospacemed.com), an emerging medical technology company based in Paris, and Oldelft Benelux, a renowned specialist in medical diagnostic imaging, announced today the signature of an exclusive distribution agreement of EOS, the world's first ultra-low-dose 2D|3D imager. The agreement will cover the distribution of EOS for the Benelux area (Belgium, The Netherlands & Luxembourg).
"The installation of our ultra-low-dose EOS imager in the University Medical Center Groningen, one of the largest hospitals in The Netherlands, has clearly demonstrated the great interest of the Dutch medical community for our breakthrough technology. We are very enthusiastic about this agreement with a key player in the Benelux medical imaging field," said Peter Cardle, biospace med's Vice President of Sales.
"We are extremely pleased to announce this new distribution agreement, as it will help biospace med to penetrate exciting new markets in Europe," said Marie Meynadier, Ph.D., chief executive officer of biospace med. "The recent progress we have made in new-site installations across the globe, combined with the clinical coverage in major congresses last year, is demonstrating that EOS is no longer a nice-to-have product but clearly a must-have, specifically in dose irradiation. EOS uses dramatically less radiation than a conventional x-ray or CT scan and thus represents an extraordinary enhancement in musculoskeletal imaging—as all other imaging modalities deliver a substantial dose of radiation to the patient," added Dr. Meynadier.
"We are very pleased to have acquired the distributorship for EOS," said Guido Geerts, Msc., managing director of Oldelft Benelux. "The EOS system is a valuable asset to our product portfolio. The system fits seamlessly in our strategy to offer low-dose systems in a high-end market, especially since the discussion on dose and dose reduction have become more important again recently."
About biospace med
biospace med was founded on a unique partnership between Nobel Prize-winning physicist Georges Charpak, Ph.D., and a team of biomedical engineers, orthopedic surgeons and radiologists who developed a complete orthopedic imaging solution. The Company's lead product, EOS ultra-low-dose 2D/3D imager, allows full-body imaging of patients in a weight-bearing position that enables global assessment of balance and posture. The sterEOS workstation enables 3D bone-envelope-modeling in a weight-bearing position and provides over 100 clinical parameters to the orthopedic surgeon for pre- and post-operative surgical planning. EOS and sterEOS offer a total solution in orthopedic imaging now available in the U.S. since receiving FDA 510(k) clearance. The Company has corporate headquarters in Cambridge, Mass. (185 Alewife Brook Parkway, Suite 410; toll-free: +1-866-933-5301), and Paris, as well as an office in Montreal, and is targeting a $2 billion orthopedic imaging marketplace.
Farmavita.Net
